NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 104 filers reported holding NURIX THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $154,017 | -2.1% | 19,595 | +24.4% | 0.00% | – |
| Q2 2023 | $157,382 | -37.6% | 15,754 | -44.6% | 0.00% | – |
| Q1 2023 | $252,308 | +16.4% | 28,413 | +43.9% | 0.00% | – |
| Q4 2022 | $216,811 | -14.3% | 19,746 | +1.6% | 0.00% | – |
| Q3 2022 | $253,000 | -4.9% | 19,436 | -7.3% | 0.00% | – |
| Q2 2022 | $266,000 | +5.6% | 20,963 | +16.8% | 0.00% | – |
| Q1 2022 | $252,000 | -56.4% | 17,952 | -10.1% | 0.00% | – |
| Q4 2021 | $578,000 | 0.0% | 19,970 | +3.5% | 0.00% | – |
| Q3 2021 | $578,000 | +9.7% | 19,293 | -2.9% | 0.00% | – |
| Q2 2021 | $527,000 | +7.6% | 19,875 | +26.2% | 0.00% | – |
| Q1 2021 | $490,000 | +14.2% | 15,745 | +20.8% | 0.00% | – |
| Q4 2020 | $429,000 | +107.2% | 13,036 | +119.8% | 0.00% | – |
| Q3 2020 | $207,000 | – | 5,931 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |